Document:

exv10w3

 

Exhibit 10.3

FOUNDRY NETWORKS, INC.

CHANGE OF CONTROL SEVERANCE AGREEMENT

     This Change of Control Severance Agreement (the “Agreement”) is made and entered into by and
between                      (“Executive”) and Foundry Networks, Inc. (the “Company”), effective as of
December 5, 2007 (the “Effective Date”).

RECITALS

     1. It is expected that the Company from time to time will consider the possibility of an
acquisition by another company or other change of control. The Board of Directors of the Company
(the “Board”) recognizes that such consideration can be a distraction to Executive and can cause
Executive to consider alternative employment opportunities. The Board has determined that it is in
the best interests of the Company and its stockholders to assure that the Company will have the
continued dedication and objectivity of Executive, notwithstanding the possibility, threat or
occurrence of a Change of Control (as defined herein) of the Company.

     2. The Board believes that it is in the best interests of the Company and its stockholders to
provide Executive with an incentive to continue his or her employment and to motivate Executive to
maximize the value of the Company upon a Change of Control for the benefit of its stockholders.

     3. The Board believes that it is imperative to provide Executive with certain severance
benefits upon Executive’s termination of employment in Connection a Change of Control. These
benefits will provide Executive with enhanced financial security and incentive and encouragement to
remain with the Company notwithstanding the possibility of a Change of Control.

     4. Certain capitalized terms used in the Agreement are defined in Section 6 below.

AGREEMENT

     NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto
agree as follows:

     1. Term of Agreement. This Agreement will have a term of three (3) years commencing
on the Effective Date and ending on the third anniversary of the Effective Date (the “Expiration
Date”), and if not amended or renewed by the Board prior to the Expiration Date, this Agreement
shall terminate automatically on such Expiration Date. Notwithstanding the foregoing, the Company
agrees that after the second anniversary of the Effective Date, the Compensation Committee of the
Board (the “Committee”) shall undertake to review the Agreement and the benefits provided
thereunder in good faith, with the assistance of the Company’s outside advisors and compensation
consultants, in order to ascertain, based upon the then current market conditions or any other
factors deemed relevant by the Board and the Committee, the appropriateness of continuing the
Agreement after the Expiration Date or whether it would be more appropriate for the Company and its
stockholders to amend or terminate the Agreement as of the Expiration Date.

 

 

     2. At-Will Employment. The Company and Executive acknowledge that Executive’s
employment is and will continue to be at-will, as defined under applicable law. If Executive’s
employment terminates for any reason, including (without limitation) any termination not otherwise
in Connection with a Change of Control, Executive will not be entitled to any payments, benefits,
damages, awards or compensation other than as provided by this Agreement.

     3. Severance Benefits.

          (a) Involuntary Termination in Connection with a Change of Control. If in Connection
with a Change of Control (i) Executive terminates his or her employment with the Company (or any
parent, subsidiary or successor of the Company) for “Good Reason” (as defined herein) or (ii) the
Company (or any parent, subsidiary or successor of the Company) terminates Executive’s employment
without “Cause” (as defined herein) and Executive signs and does not revoke the release of claims
required by Section 4, Executive will receive the following severance benefits from the Company:

               (i) Severance Payment. Executive will receive a single lump sum payment of severance
pay (less applicable withholding taxes) equal to twelve (12) months of Executive’s annual base
salary (as in effect immediately prior to (A) the Change of Control, or (B) Executive’s
termination, whichever is greater).

               (ii) Equity Awards. One hundred percent (100%) of Executive’s then outstanding and
unvested awards relating to the Company’s common stock (whether stock options, stock appreciation
rights, shares of restricted stock, restricted stock units, or otherwise (collectively, the “Equity
Awards”)) as of the date of Executive’s termination of employment will become vested and will
otherwise remain subject to the terms and conditions of the applicable Equity Award agreement. In
addition, the post-termination exercise period for any outstanding stock option and/or stock
appreciation right shall be extended so as to terminate on the first to occur of (1) twelve (12)
months from the date of Executive’s termination, or (2) the stock option and/or stock appreciation
rights original term expiration (e.g., the awards original ten (10) year expiration date).
Notwithstanding the foregoing, if (A) in a Change of Control the acquirer refuses to assume
Executive’s Equity Awards and/or refuses to substitute such Equity Awards with equivalent awards
reflecting acquirer’s stock, or (B) in a Change of Control where the acquirer is not a publicly
traded corporation as defined in Section 162(m)(2) of the Code (regardless of whether or not such
acquirer is willing to assume the Equity Awards), then one hundred percent (100%) of Executive’s
Equity Awards outstanding as of the Change of Control will become vested immediately prior to the
effective date of the Change of Control.

               (iii) Benefits. The Company agrees to reimburse Executive for the same level of
health coverage and benefits as in effect for Executive on the day immediately preceding the date
of termination; provided, however, that (1) Executive constitutes a qualified beneficiary, as
defined in Section 4980(B)(g)(1) of the Internal Revenue Code of 1986, as amended; and
(2) Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (“COBRA”), within the time period prescribed pursuant to
COBRA. The Company will continue to reimburse Executive for continuation coverage through the
earlier of (A) the date twelve (12) months after the termination date, or (B) the date upon which

-2-

 

Executive and Executive’s eligible dependents become covered under similar plans. Executive
will thereafter be responsible for the payment of COBRA premiums (including, without limitation,
all administrative expenses) for the remaining COBRA period.

               (iv) Personal Computer. The Company agrees, if Executive so desires, to transfer
possession and title to the Executive of the Company provided personal computer and cellular phone
and/or other mobile e-mail device used by Executive as of the date of termination. The Company
also will agree to transfer and/or provide to Executive the applicable software licenses for all
current software applications installed on the Company provided personal computer.

               (v) Additional Entitlements. Executive will also receive: (i) unpaid base salary
through the date of termination; (ii) an additional payment equal to the current year’s annual
incentive pro-rated to the date of termination, with such pro-rated amount to be calculated by
multiplying the current year’s target incentive level by a fraction with a numerator equal to the
number of days between the start of the current fiscal year and the date of termination and a
denominator equal to 365; (iii) Executive’s accrued and unused vacation time, if any, through the
date of termination; and (iv) other payments and benefits, if any, in accordance with applicable
plans, programs and other arrangements of the Company. The payments to be made pursuant to clauses
(i) through (iv) above shall be made in a single cash lump sum by no later than ten (10) business
days following Executive’s termination date.

          (b) Timing of Severance Payments. Unless otherwise required pursuant to Section 10 of
this Agreement, the Company will pay the severance payments and benefits, as applicable, specified
in Section 3(a) of this Agreement, in a lump sum as soon as practicable following the date of
termination. If Executive should die before all of the severance amounts have been paid, such
unpaid amounts will be paid in a lump-sum payment (less any withholding taxes) to Executive’s
designated beneficiary, if living, or otherwise to the personal representative of Executive’s
estate.

          (c) Terminations Other Than in Connection with a Change of Control. If Executive’s
employment with the Company terminates for any reason other than those provided for in Section 3 of
this Agreement, then Executive will not be entitled to receive severance or other benefits except
for those (if any) as may then be established under the Company’s then existing severance and
benefits plans and practices or pursuant to other written agreements with the Company, including,
without limitation, any equity award agreement.

          (d) Disability; Death. If the Company terminates Executive’s employment as a result
of Executive’s Disability, or Executive’s employment terminates due to his or her death, then
Executive will not be entitled to receive severance or other benefits except for those (if any) as
may then be established under the Company’s then existing written severance and benefits plans and
practices or pursuant to other written agreements with the Company, including, without limitation,
any equity award agreement.

          (e) Exclusive Remedy. In the event of a termination of Executive’s employment in
Connection with a Change of Control, the provisions of this Section 3 are intended to be and are
exclusive and in lieu of any other rights or remedies to which Executive or the Company may

-3-

 

otherwise be entitled, whether at law, tort or contract, in equity, or under this Agreement.
Executive will be entitled to no benefits, compensation or other payments or rights upon
termination of employment other than those benefits expressly set forth in this Section 3, except
as may be provided in any Equity Award agreement.

     4. Conditions to Receipt of Severance.

          (a) Release of Claims Agreement. The receipt of any severance or other benefits
pursuant to Section 3 will be subject to Executive signing and not revoking a release of claims
agreement in substantially the form attached as Exhibit A, but with any appropriate
reasonable modifications, reflecting changes in applicable law, as is necessary to provide the
Company with the protection it would have if the release of claims were executed as of the
Effective Date. No severance or other benefits will be paid or provided until the release of
claims agreement becomes effective, and any severance amounts or benefits otherwise payable between
the date of Executive’s termination and the date such release becomes effective shall be paid on
the effective date of such release. Notwithstanding the foregoing, or any provision of this
Agreement to the contrary, the release of claims agreement must be signed by March 15th
of the year following the year of Executive’s termination of employment.

          (b) Non-solicitation. The receipt of any severance or other benefits pursuant to
Section 3 will be subject to Executive’s compliance with the one (1) year non-solicitation
requirements of Section 16 of the Company’s Proprietary Information and Inventions Agreement (the
“Proprietary Agreement”).

          (c) Non-disparagement. During the twelve (12) month period beginning on the date of
Executive’s termination, Executive will not knowingly and materially disparage, criticize, or
otherwise make any derogatory statements regarding the Company. During the twelve (12) month
period beginning on the Executive’s termination date, the Company will not knowingly and materially
disparage, criticize, or otherwise make any derogatory statements regarding Executive.
Notwithstanding the foregoing, nothing contained in this Agreement will be deemed to restrict
Executive, the Company or any of the Company’s current or former officers and/or directors from (1)
providing information to any governmental or regulatory agency (or in any way limit the content of
any such information) to the extent they are requested or required to provide such information
pursuant to applicable law or regulation or (2) enforcing his or its rights pursuant to this
Agreement.

          (d) Other Requirements. Executive’s receipt of any payments or benefits under Section
3 will be subject to Executive continuing to comply with the terms of any form of confidential
information agreement and the provisions of this Section 4.

          (e) No Duty to Mitigate. Executive will not be required to mitigate the amount of any
payment contemplated by this Agreement, nor will any earnings that Executive may receive from any
other source reduce any such payment.

     5. Limitation on Payments. In the event that the severance and other benefits
provided for in this Agreement or otherwise payable to Executive (i) constitute “parachute
payments” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the
“Code”) and

-4-

 

(ii) but for this Section 5, would be subject to the excise tax imposed by Section 4999 of the
Code, then Executive’s severance benefits under Section 3 will be either:

(a) delivered in full, or

(b) delivered as to such lesser extent which would result in no
portion of such severance benefits being subject to excise tax under Section
4999 of the Code,

whichever of the foregoing amounts, taking into account the applicable federal, state and local
income taxes and the excise tax imposed by Section 4999, results in the receipt by Executive on an
after-tax basis, of the greatest amount of severance benefits, notwithstanding that all or some
portion of such severance benefits may be taxable under Section 4999 of the Code. Unless the
Company and Executive otherwise agree in writing, any determination required under this Section 5
will be made in writing by the Company’s independent public accountants immediately prior to Change
of Control (the “Accountants”), whose determination will be conclusive and binding upon Executive
and the Company for all purposes. For purposes of making the calculations required by this
Section 5, the Accountants may make reasonable assumptions and approximations concerning applicable
taxes and may rely on reasonable, good faith interpretations concerning the application of Sections
280G and 4999 of the Code. The Company and Executive will furnish to the Accountants such
information and documents as the Accountants may reasonably request in order to make a
determination under this Section. The Company will bear all costs the Accountants may reasonably
incur in connection with any calculations contemplated by this Section 5.

     6. Definition of Terms. The following terms referred to in this Agreement will have
the following meanings:

          (a) Cause. For purposes of this Agreement, “Cause” will mean:

               (i) Executive’s willful and continued failure to perform the duties and responsibilities of
his position (other than as a result of Executive’s illness or injury) after there has been
delivered to Executive a written demand for performance from the Board which describes the basis
for the Board’s belief that Executive has not substantially performed his duties and provides
Executive with thirty (30) days to take corrective action;

               (ii) Any material act of personal dishonesty taken by Executive in connection with his
responsibilities as an employee of the Company with the intention that such action may result in
the substantial personal enrichment of Executive;

               (iii) Executive’s conviction of, or plea of nolo contendere to, a felony that the Board
reasonably believes has had or will have a material detrimental effect on the Company’s reputation
or business;

               (iv) A willful breach of any fiduciary duty owed to the Company by Executive that has a
material detrimental effect on the Company’s reputation or business;

               (v) Executive being found liable in any Securities and Exchange Commission or other civil or
criminal securities law action (regardless of whether or not Executive

-5-

 

admits or denies liability), which the Board determines, in its reasonable discretion, will
have a material detrimental effect on the Company’s reputation or business;

               (vi) Executive entering any cease and desist order with respect to any action which would bar
Executive from service as an executive officer or member of a board of directors of any
publicly-traded company (regardless of whether or not Executive admits or denies liability);

               (vii) Executive (A) obstructing or impeding; (B) endeavoring to obstruct or impede, or (C)
failing to materially cooperate with, any investigation authorized by the Board or any governmental
or self-regulatory entity (an “Investigation”). However, Executive’s failure to waive
attorney-client privilege relating to communications with Executive’s own attorney in connection
with an Investigation will not constitute “Cause”; or

               (viii) Executive’s disqualification or bar by any governmental or self-regulatory authority
from serving in Executive’s position with the Company, if (A) the disqualification or bar continues
for more than thirty (30) days, and (B) during that period the Company uses its commercially
reasonable efforts to cause the disqualification or bar to be lifted. While any disqualification or
bar continues during Executive’s employment, Executive will serve in the capacity contemplated by
this Agreement to whatever extent legally permissible and, if Executive’s employment is not
permissible, Executive will be placed on administrative leave (which will be paid to the extent
legally permissible).

Other than for a termination pursuant to Section 6(a)(iii), Executive shall receive notice and an
opportunity to be heard before the Board with Executive’s own attorney before any termination for
Cause is deemed effective. Notwithstanding anything to the contrary, the Board may immediately
place Executive on administrative leave (with full pay and benefits to the extent legally
permissible) and suspend all access to Company information, employees and business should Executive
wish to avail himself of his opportunity to be heard before the Board prior to the Board’s
termination for Cause. If Executive avails himself of his opportunity to be heard before the
Board, (A) the Board may, in its sole and absolute discretion, provide Executive with reasonable
access to Company information and employees in order to help Executive prepare for the opportunity
to be heard before the Board, (B), however, if Executive then fails to make himself available to
the Board within ten (10) business days of such request to be heard, the Board may thereafter
cancel the administrative leave and terminate Executive for Cause.

          (b) Change of Control. For purposes of this Agreement, “Change of Control” shall mean
the occurrence of any of the following events:

               (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”)) becomes the “beneficial owner” (as defined in Rule
13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more
than fifty percent (50%) of the total voting power represented by the Company’s then outstanding
voting securities; or

-6-

 

               (ii) The consummation of the sale or disposition by the Company of all or substantially all of
the Company’s assets; or

               (iii) A change in the composition of the Board occurring within a one-year period, as a result
of which fewer than a majority of the directors are Incumbent Directors. “Incumbent Directors”
means directors who either (A) are Directors as of the effective date of this Agreement, or (B) are
elected, or nominated for election, to the Board with the affirmative votes of at least a majority
of the Directors at the time of such election or nomination (but will not include an individual
whose election or nomination is in connection with an actual or threatened proxy contest relating
to the election of directors to the Company); or

               (iv) The consummation of a merger or consolidation of the Company with any other corporation,
other than a merger or consolidation which would result in the voting securities of the Company
outstanding immediately prior thereto continuing to represent (either by remaining outstanding or
by being converted into voting securities of the surviving entity or its parent) at least fifty
percent (50%) of the total voting power represented by the voting securities of the Company or such
surviving entity or its parent outstanding immediately after such merger or consolidation.

          (c) Disability. For purposes of this Agreement, “Disability” shall mean a condition
of Executive whereby Executive either: (i) is unable to engage in any substantial gainful activity
by reason of any medically determinable physical or mental impairment which can be expected to
result in death or can be expected to last for a continuous period of not less than twelve (12)
months, or (ii) is, by reason of any medically determinable physical or mental impairment which can
be expected to result in death or can be expected to last for a continuous period of not less than
twelve (12) months, receiving income replacement benefits for a period of not less than three (3)
months under a long-term disability plan, if any, covering employees of the Company.

          (d) Good Reason. For purposes of this Agreement, “Good Reason” means the occurrence
of any of the following, without Executive’s express written consent:

               (i) A significant reduction of Executive’s responsibilities and duties, relative to
Executive’s responsibilities and duties in effect immediately prior to such reduction, provided,
however, that a reduction in responsibilities, or a change in duties, by virtue of the Company
being acquired and made part of another entity (as, for example, when the chief executive officer
of the Company remains as the senior executive officer of a division or subsidiary of the acquirer
which division or subdivision either contains substantially all of the Company’s business or is of
a comparable size), shall not be considered “Good Reason” for purposes of this Agreement;

               (ii) A material and significant reduction in Executive’s base salary or target annual
incentive as in effect immediately prior to such reduction other than pursuant to a reduction that
also is applied to substantially all other executive officers of the Company and which reduction
reduces the base salary and/or target annual incentive by a percentage reduction that is no greater
than 10%;

-7-

 

               (iii) The relocation of Executive to a facility or location more than thirty-five (35) miles
from his primary place of employment;

               (iv) Any purported termination of the Executive’s employment for “Cause” without first
satisfying the procedural protections, as applicable, required by the definition of “Cause” in this
Agreement; or

               (v) The failure of the Company to obtain the assumption of this Agreement by a successor
and/or acquirer and an agreement that Executive will retain the substantially similar
responsibilities in the acquirer or the merged or surviving company as he had prior to the
transaction.

The notification and placement of Executive on administrative leave pending a potential
determination by the Board that Executive may be terminated for Cause shall not constitute Good
Reason for purposes of this Agreement.

Executive will not resign for Good Reason without first providing the Company with written notice
within sixty (60) days of the event that Executive believes constitutes “Good Reason” specifically
identifying the acts or omissions constituting the grounds for Good Reason and a reasonable cure
period of not less than thirty (30) days following the date of such notice.

          (e) In Connection with a Change of Control. For purposes of this Agreement, a
termination of Executive’s employment with the Company is “in Connection with a Change of Control”
if Executive’s employment is terminated within either (A) three (3) months prior to the
consummation of a Change of Control, or (B) twelve (12) months following a Change of Control.

          (f) Section 409A Limit. For purposes of this Agreement, “Section 409A Limit” will
mean the lesser of two (2) times: (i) Executive’s annualized compensation based upon the annual
rate of pay paid to Executive during the Company’s taxable year preceding the Company’s taxable
year of Executive’s termination of employment as determined under Treasury Regulation
1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or
(ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section
401(a)(17) of the Internal Revenue Code for the year in which Executive’s employment is terminated.

     7. Successors.

          (a) The Company’s Successors. Any successor to the Company (whether direct or
indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or
substantially all of the Company’s business and/or assets will assume the obligations under this
Agreement and agree expressly to perform the obligations under this Agreement in the same manner
and to the same extent as the Company would be required to perform such obligations in the absence
of a succession. For all purposes under this Agreement, the term “Company” will include any
successor to the Company’s business and/or assets which executes and delivers the assumption
agreement described in this Section 7(a) or which becomes bound by the terms of this Agreement by
operation of law.

-8-

 

          (b) Executive’s Successors. The terms of this Agreement and all rights of Executive
hereunder will inure to the benefit of, and be enforceable by, Executive’s personal or legal
representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.

     8. Notice.

          (a) General. Notices and all other communications contemplated by this Agreement will
be in writing and will be deemed to have been duly given when personally delivered or when mailed
by U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of
Executive, mailed notices will be addressed to him or her at the home address which he or she most
recently communicated to the Company in writing. In the case of the Company, mailed notices will
be addressed to its corporate headquarters, and all notices will be directed to the attention of
its President.

          (b) Notice of Termination. Any termination by the Company for Cause or by Executive
for Good Reason or as a result of a voluntary resignation will be communicated by a notice of
termination to the other party hereto given in accordance with Section 8(a) of this Agreement.
Such notice will indicate the specific termination provision in this Agreement relied upon, will
set forth in reasonable detail the facts and circumstances claimed to provide a basis for
termination under the provision so indicated, and will specify the termination date. The failure
by Executive to include in the notice any fact or circumstance which contributes to a showing of
Good Reason will not waive any right of Executive hereunder or preclude Executive from asserting
such fact or circumstance in enforcing his or her rights hereunder.

     9. Arbitration. The Company and the Executive each agree that any and all disputes
arising out of the terms of this Agreement, Executive’s employment by the Company, Executive’s
service as an officer or director of the Company, or Executive’s compensation and benefits, their
interpretation and any of the matters herein released, will be subject to binding arbitration. In
the event of a dispute, the parties (or their legal representatives) will promptly confer to select
a single arbitrator mutually acceptable to both parties. If the parties cannot agree on an
arbitrator, then the moving party may file a demand for arbitration with the American Arbitration
Association (“AAA”) in Santa Clara County, California, who will be selected and appointed
consistent with the AAA-Employment Dispute Resolution Rules, except that such arbitrator must have
the qualifications set forth in this paragraph. Any arbitration will be conducted in a manner
consistent with AAA National Rules for the Resolution of Employment Disputes, supplemented by the
California Rules of Civil Procedure. The parties further agree that the prevailing party in any
arbitration will be entitled to injunctive relief in any court of competent jurisdiction to enforce
the arbitration award. The parties hereby agree to waive their right to have any dispute between
them resolved in a court of law by a judge or jury. This paragraph will not prevent either party
from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction
over the parties and the subject matter of their dispute relating to Executive’s obligations under
this Agreement and the Company’s form of confidential information agreement.

     10. Code Section 409A. Notwithstanding anything to the contrary in this Agreement, if
Executive is a “specified employee” within the meaning of Section 409A of the Code and any final
regulations and guidance promulgated thereunder (collectively “Section 409A”) at the time of

-9-

 

Executive’s termination, and the severance payable to Executive, if any, pursuant to this
Agreement, when considered together with any other severance payments or separation benefits may be
considered deferred compensation under Section 409A (together, the “Deferred Compensation
Separation Benefits”), then only that portion of the Deferred Compensation Separation Benefits
which do not exceed the Section 409A Limit (as defined herein) may be made within the first six (6)
months following Executive’s termination of employment in accordance with the payment schedule
applicable to each payment or benefit. Any portion of the Deferred Compensation Separation
Benefits in excess of the Section 409A Limit otherwise due to Executive on or within the six (6)
month period following Executive’s termination will accrue during such six (6) month period and
will become payable in a lump sum payment on the date six (6) months and one (1) day following the
date of Executive’s termination of employment. All subsequent Deferred Compensation Separation
Benefits, if any, will be payable in accordance with the payment schedule applicable to each
payment or benefit. It is the intent of this Agreement to comply with the requirements of Section
409A so that none of the severance payments and benefits to be provided hereunder will be subject
to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to
so comply.

     11. Miscellaneous Provisions.

          (a) Waiver. No provision of this Agreement will be modified, waived or discharged
unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by
an authorized officer of the Company (other than Executive). No waiver by either party of any
breach of, or of compliance with, any condition or provision of this Agreement by the other party
will be considered a waiver of any other condition or provision or of the same condition or
provision at another time.

          (b) Headings. All captions and section headings used in this Agreement are for
convenient reference only and do not form a part of this Agreement.

          (c) Choice of Law. The validity, interpretation, construction and performance of this
Agreement will be governed by the laws of the State of California (with the exception of its
conflict of laws provisions).

          (d) Integration. This Agreement, together with the Proprietary Agreement and the
standard forms of Equity Award agreement that describe Executive’s outstanding Equity Awards,
represents the entire agreement and understanding between the parties as to the subject matter
herein and supersedes all prior or contemporaneous agreements whether written or oral. No waiver,
alteration, or modification of any of the provisions of this Agreement will be binding unless in a
writing and signed by duly authorized representatives of the parties hereto. In entering into this
Agreement, no party has relied on or made any representation, warranty, inducement, promise, or
understanding that is not in this Agreement. To the extent that any provisions of this Agreement
conflict with those of any other agreement between the Executive and the Company, the terms in this
Agreement will prevail.

          (e) Severability. In the event that any provision or any portion of any provision
hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable, or

-10-

 

void, this Agreement will continue in full force and effect without said provision or portion
of provision. The remainder of this Agreement shall be interpreted so as best to effect the intent
of the Company and Executive.

          (f) Withholding. All payments made pursuant to this Agreement will be subject to
withholding of applicable income and employment taxes.

          (g) Counterparts. This Agreement may be executed in counterparts, each of which will
be deemed an original, but all of which together will constitute one and the same instrument.

-11-

 

     IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the
Company by its duly authorized officer, as of the day and year set forth below.

	 	 	 	 	 	 	 	 	 
	COMPANY	 	 	 	FOUNDRY NETWORKS, INC.  
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	EXECUTIVE

	 	 	 	By:	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 	 	 

-12-exv10w1

 

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.

Exhibit 10.1

	 	 	 	 	 
	 

	 	447 March Road
	 	Tel: +1 613 592-2790
	 

	 	Ottawa, Ontario
	 	Fax: +1 613 592-6937
	 

	 	K2K 1X8 Canada	 	 
	 

	 	www.mdsnordion.com	 	 

November 28, 2007

Alseres Pharmaceuticals Inc.

85 Main Street

Hopkinton, MA 01748

USA

Dear Sirs,

	 	 	 	 	 
	Re:

	 	Amendment #8 to Agreement between MDS Nordion, a division of MDS (Canada) Inc.,
	 	 
	 

	 	dated the
9th day of August, 2000, as amended (the “Agreement”).	 	 
	 

	 	 	 	 

Reference is made to the agreement between MDS Nordion and Alseres Pharmaceuticals Inc. (ALSE)
dated the 9th day of August, 2000 (the “Agreement”).

In consideration of $1.00 and other valuable consideration the sufficiency of which is hereby
acknowledged, the parties desire to further amend the Agreement and extend the term.

	 	1.	 	As of the 8th day of June 2007, Boston Life Sciences changed its
name to Alseres Pharmaceuticals, Inc. (“ALSE”). All references to Boston Life Sciences
or BLSI in the Agreement shall now be replaced accordingly.
	 
	 	2.	 	Section 16.1 of the Agreement shall be amended in its entirety and shall read
as follows:
	 
	 	 	 	“The term of this Agreement shall commence upon the Effective Date, and unless
terminated earlier pursuant to this Agreement, shall expire on the earlier of (i)
FDA granting ALSE’s NDA with respect to Altropane for Parkinson’s Disease or (ii)
December 31, 2008.”
	 
	 	3.	 	In addition to the Maximum Batch Size available for purchase as identified in
Section 4.1 of the agreement, during the period of January 1, 2008 through December 31,
2008, ALSE agrees to purchase and MDS Nordion agrees to supply Altropane under the
Agreement in accordance with the terms and batch size appearing on the face of MDS
Nordion’s Quotation 2007-RQ-0276 (attached) and as amended from time to time. The
Terms and Conditions on the second page of the quotation shall not apply.

All other Terms and Conditions in this agreement shall remain in full force and effect.

The foregoing amendments and agreement shall be effective as of the date first written above.

-1-

 

In you agree with the foregoing, please execute this Agreement in the space provided below.

Sincerely,

Mihran Zaroukian

Senior Program Manager

MDS Nordion

	 	 	 	 	 
	 	 	 
	Per:  	/s/ Phil Larabie   Nov 30/07
 	 	 
	 	 	 	 

Name: Phil Larabie

Title: Vice President, Business Development

	 	 	 	 	 	 	 
	 

	 	We agree this 4th day of December, 2007	 
	 
	 	 	 	 	 	 
	 

	 	Alseres Pharmaceuticals Inc.
	 
	 
	 	 	 	 	 	 
	 

	 	Per:
	 	/s/ Kenneth L. Rice Jr.	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:
	 	Kenneth L. Rice Jr.	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:
	 	EVP & CFO	 	 
	 

	 	 	 	 	 	 

-2-

 

	QUOTATION            FROM: MDS NORDION
PRO-FORMA INVOICE            DATE: 2007 November 14
TO: Alseres Pharmaceuticals, OUR REFERENCE:
Inc. 2007-RQ-0276
85 Main Street YOUR REFERENCE:
Hopkinton, MA
USA 01748
Attention: Dr. Richard Thorn
ITEM            DESCRIPTION
——  —

	1.0 QUOTATION FOR THE SUPPLY OF BATCHES OF ALTROPANE FROM JANUARY 1, 2008 UNTIL DECEMBER 31,
2008.
Batch Description : up to 20 shippable doses of Altropane (Note 1)
Price : $[**] per batch
Minimum [**] Batches monthly (minimum charge of
$[**] per month)
Freight Charges : Prepaid and charged as incurred. AIRNET is
recommended.
Notes:
1. An Altropane dose contains 5 mCi of I-123 as of 15:00 hrs PT., the day after
manufacture. Additional product specifications are as outlined in the Agreement.
UNLESS OTHERWISE STATED, PRICES DO NOT INCLUDE ANY TAXES OR DUTY. THIS QUOTATION IS SUBJECT TO TERMS ON
THE FACE AND SECOND PAGE.
—
SHIPPING SCHEDULE: DELIVERY:
As Requested By Customer Ex-Works Vancouver, BC
—
CURRENCY:
United States Dollars
—
TERMS (SEE SECOND PAGE): QUOTATION VALID UNTIL:
Net 30 Days 2007 December 31
——  —
ISSUED ON BEHALF OF MDS NORDION
MIHRAN ZAROUKIAN, PROGRAM MANAGER, MDS NORDION
—

 

 

Applicable to radioisotope and radiopharmaceutical sales by MDS Nordion herein referred to as MDS
Nordion

	1.	 	QUOTATIONS

A
quotation shall supersede all previous quotations relating to the same subject matter and
shall become void unless accepted by the buyer (“Buyer”) on or before the date indicated on
the face hereof, or, if no such date appears, on the sixtieth (60th) day following
the date of such quotation. A quotation may be withdrawn or amended upon notice at any time
prior to MDS Nordion’s acceptance of the Buyer’s order.

Buyer shall indicated acceptance of a quotation by using its purchase order, or other instrument,
specifically referencing the quotation issued by MDS Nordion.

	2.	 	TERMS & CONDITIONS

Any terms and conditions in the Buyer’s order additional to or different from those appearing
herein shall be deemed to be objected to by MDS Nordion and shall be of no effect unless
accepted by MDS Nordion as provided herein. In the absence of prior agreement between MDS
Nordion and the Buyer, acceptance of delivery by the Buyer of the products shall be deemed to
be acceptance of these terms and conditions.

	3.	 	PRICES

Prices and charges quoted are valid only for the transaction specified on the face hereof and are
exclusive of all taxes, duties or other charges. Buyer shall pay or reimburse MDS Nordion in
respect of the latter amounts.

	4.	 	DELAYS

Failure by the Buyer to accept delivery of any shipment shall entitled MDS Nordion to charge the
Buyer for all additional expenses incurred thereby and the Buyer shall bear the risk and
expense of such shipment until delivery, manufacturing or installation arising from unforeseen
circumstances or from causes beyond its control. MDS Nordion’s delivery obligation shall be
extended by a period equal to the length of such delay. In the event of any product shortage
arising from such delays, MDS Nordion reserves the right to allocate its products among its
customers as it deems equitable.

	5.	 	PACKING

All products shall be packed for shipment in accordance with standard MDS Nordion practice and in
conformity with applicable regulations.

	6.	 	DELIVERY

Delivery shall occur at the location stipulated on the face hereof. Title to and risk of loss in
respect of the product shall pass to the Buyer on delivery. MDS Nordion may inure, at Buyer’s
expense, the full value of all products delivered until MDS Nordion has been paid in full or
until such products have been returned to MDS Nordion. MDS Nordion may suspend its delivery
obligation without prejudice to its rights against the Buyer, if it determines that the
financial condition of the Buyer warrants such action and may repudiate such obligation if
satisfactory action is not taken by the Buyer within 5 days of notice thereof from MDS
Nordion.

	7.	 	INVOICES AND PAYMENT

Prices and currency shall be as set out in the quotation and payment thereof shall be net 30 days
from invoice date. Invoices may be submitted by MDS Nordion upon shipment of the product.
Buyer shall pay interest on overdue accounts at an annual rate of eighteen percent (18%) or
the maximum allowed by law, whichever is the lesser. MDS Nordion shall retain a purchase
money security interest, or vendor’s lien as the case may be, on the product until such time
as MDS Nordion has been paid in full thereof. The Buyer will do all things and provide all
documents necessary to register such interest.

	8.	 	WARRANTY

	 	A)	 	MDS Nordion makes the following warranties with respect to its products:

	 	1.	 	Sealed Sources: Sealed sources shall conform to
current MDS Nordion specifications and shall be free from any material defect
in workmanship or materials specified calibration times or at the time of
delivery, as the case may be.
	 
	 	2.	 	Radioisotopes and Radiopharmaceuticals: Such products
shall comply with

 

 

applicable government regulations and current MDS Nordion specifications at
the specified calibration time of delivery, as the case may be.

	 	B)	 	All warranty claims shall be made by the Buyer within either thirty (30) days
of receipt of the product or the half-life of the product, whichever period is shorter.
MDS Nordion may request, at its cost, the return of any product in respect of which a
warranty claim is made.
	 
	 	C)	 	All Warranty obligations of MDS Nordion shall cease and have no effect if the
products are subject to accident, abuse, misuse, alteration or neglect.
	 
	 	D)	 	MDS Nordion’s only obligation with respect to the warranties herein shall be to
repair, or at its sole discretion, to replace defective products or parts thereof.
	 
	 	E)	 	THE WARRANTIES CONTAINED HEREIN ARE EXPRESSLY IN LIEU OF AND EXCLUDE ALL OTHER
EXPRESS OR IMPLIED WARRANTIES INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, USE OR APPLICATION.

	10.	 	PRODUCT INFORMATION

Buyer acknowledges that it has received and is familiar with MDS Nordion’s labeling and literature
concerning the product and shall distribute such information to those of its employees, agents
or customers who handle, process or sell such product.

	11.	 	LIMITATION OF DAMAGES AND LIABILITY

MDS NORDION’S LIABILITY TO THE BUYER FOR DAMAGES, HOWSOEVER CAUSED, SHALL NOT EXCEED PAYMENT
ACTUALLY RECEIVED BY MDS NORDION FOR THE PRODUCT FURNISHED, OR TO BE FURNISHED, AS THE CASE
MAY BE, AND IN NO EVENT SHALL MDS NORDION BE LIABLE FOR INDIRECT, CONTINGENT, SPECIAL OR
CONSEQUENTIAL DAMAGES (INCLUDING LOSS OF PROFIT).

Sealed sources (Ir-192) must be kept clean and dry. MDS Nordion shall not be held liable for any
damages resulting from misuse or failure to maintain sources in accordance with MDS Nordion’s
Operating Procedure IS/OP 0045C000.

Notwithstanding the foregoing, liability for bodily injury, or death, shall be determined by the
applicable law, but each of MDS Nordion and the Buyer agrees to indemnify and hold the other
harmless in respect of that portion of such liability attributable to its conduct or that of
its directors, officers, agents and employees.

	12.	 	PATENT INDEMNITY

MDS Nordion shall defend any suit or proceeding brought against the Buyer based on a claim that
any product, or parts thereof, manufactured or furnished by MDS Nordion hereunder constitutes
an infringement of any patent provided notice thereof is promptly given to MDS Nordion and all
necessary authority and assistance in settling and defending such claim is given to MDS
Nordion by the Buyer if it is determined or agreed that the product constitutes such an
infringement. MDS Nordion shall, at its sole discretion and expense, procure for Buyer the
right to continue using such product or parts, replace the same modified so that it becomes
non-infringing or remove said product or parts and refund an appropriate portion of the
purchase price. The foregoing shall constitute MDS Nordion’s entire liability for patent
infringement.

	13.	 	GENERAL

	 	A)	 	Neither party may assign or cancel an accepted order for product without the
written consent of the other party.
	 
	 	B)	 	The sale of products or services by MDS Nordion shall be governed by the laws
of the Province of Ontario and shall in all respects be treated as Ontario contracts.
	 
	 	C)	 	All disputes not resolved by amicable negotiation between the parties shall be
determined by arbitration in accordance with the Arbitrations Act of Ontario, Canada.
	 
	 	D)	 	No member of the House of Commons of Canada shall be admitted to any share or
part of any agreement for the supply of products or services between MDS Nordion and
the Buyer or to any benefit to arise therefrom.

 

 

	 	E)	 	In the event of any conflict between these terms and conditions and those
appearing on the face hereof, the latter shall rule.
	 
	 	F)	 	Failure by MDS Nordion to exercise any of its rights with respect to the supply
of products to the Buyer, shall not constitute a waiver or forfeiture of such rights.

	14.	 	ENTIRE AGREEMENT

These terms and conditions shall constitute the entire agreement between MDS Nordion and the Buyer
for the supply of the products. No representation, promise, agreement or condition in respect
of the products shall be binding on either party unless contained herein. Except for the
correction of stenographic or clerical errors, and notwithstanding anything in the Buyer’s
order to the contrary, no amendment of these terms and conditions shall be of any effect
unless agreed to in writing by MDS Nordion.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]